Related Experiment Videos
Canadian guidelines for the development of antidementia therapies: a conceptual summary
E Mohr1, H Feldman, S Gauthier
1Institute of Mental Health Research, University of Ottawa/Royal Ottawa Hospital, Ontario, Canada.
Abstract:
The magnitude of the problems faced by Canadian society as a result of an aging population has been identified. Perhaps the most important concern related to this greying of Canada is the increasing incidence of dementia and Alzheimer's disease. Therapeutic options for these disorders have been limited to date. Advances in biotechnology and molecular biology will offer novel approaches to treatment. These and the expansion of more traditional therapeutic avenues require guidelines with the aim of optimizing their development.
Insights
Canada
Area of Science:
- Gerontology and Public Health
- Neuroscience and Pharmacology
Background:
- Canada's aging population presents significant societal challenges.
- The increasing incidence of dementia and Alzheimer's disease is a primary concern.
Purpose of the Study:
- To address the limited therapeutic options for dementia and Alzheimer's disease.
- To outline guidelines for optimizing novel and traditional treatment development.
Main Methods:
- Review of current challenges posed by an aging population in Canada.
- Identification of emerging biotechnological and molecular biology approaches.
- Consideration of traditional therapeutic avenues.
Main Results:
- The aging demographic trend in Canada is accelerating.
- Biotechnology and molecular biology offer promising new therapeutic strategies.
- Existing treatments for dementia and Alzheimer's remain limited.
Conclusions:
- Novel therapeutic strategies are crucial for managing dementia and Alzheimer's disease in aging Canadians.
- Development guidelines are needed to advance both new and existing treatments effectively.